Information Provided By: 
Fly News Breaks for February 9, 2018
HOLX
Feb 9, 2018 | 07:15 EDT
As previously reported, Stifel analyst Jonathan Block downgraded Hologic to Hold from Buy, stating that while the stock's valuation remains compelling he is having trouble identifying sources of upside likely to take hold over the next several quarters. SculpSure's incremental market share continues to move lower and the product remains a material overhang within the Cynosure division, added Block, who lowered his price target on Hologic shares to $42 from $45.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
